Профилактика тромбоэмболических осложнений у пациентов с хронической сердечной недостаточностью


Д.А. Напалков, А.А. Соколова, А.В. Жиленко

ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова», Москва Автор для связи: Д.А. Напалков – д.м.н., проф. кафедры факультетской терапии № 1 Первого МГМУ им. И.М. Сеченова; e-mail: dminap@mail.ru
В статье обсуждаются предпосылки к повышенному тромбообразованию у пациентов с хронической сердечной недостаточностью. Особое внимание уделяется пациентам с фибрилляцией предсердий, у которых наличие сердечной недостаточности является дополнительным фактором риска тромбоэмболических осложнений. Также актуален вопрос о необходимости проведения профилактики ТЭО у пациентов с систолической недостаточностью ЛЖ и сохраненным синусовым ритмом.

Литература



  1. Maisel WH, Stevenson LW Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91:2D–8D.

  2. Boulanger CM, Vanhoutte PM. The endothelium: A pivotal role in health and cardiovascular disease. Houston, 1994:68.

  3. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalites of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: Effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation, 2001; 103:1746–51.

  4. Hoffmeister A, Hetzel J, Sander S, et al. Plasma viscosity and fibrinogen in relation to haemodynamic findings in chronic congestive heart failure. Eur J Heart Failure 1999;1:293–95.

  5. Cleland JGF. Management of thrombosis in heart failure. Heart Failure. Philadelphia: DL Mann-Saunders, 2004:653–81.

  6. Batin PD, Wickens M, Mc Entergart D, et al. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 1995;16:1613–18.

  7. Sbarouni E, Bradshaw A, Andreotti F, et al. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Amer Heart J 1994;127:607–12.

  8. Yamamoto K, Ikeda U, Turuhashi K, et al. The coagulation system is activated in dilated cardiomyopathy. J Amer Coll Cardiology 1995;25:1634–40.

  9. Cleland JGF. Management of thrombosis in heart failure. Heart Failure. Philadelphia: DL Mann-Saunders, 2004:653–81.

  10. Ridker PM, Gaboury CL. Conlin PR, et al. Stimulator of plasminogen activators inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolitic function. Circulation 1993;87:1969–73.

  11. Libby P, Simon DI. Inflammation and trombosis. The clot tkickens. Circulation 2001; 103:1718–20.

  12. Marjianowsky MU, van Lear M, Bras J, Becker AE. Chronic congestive heart failure associated with a phenotypic shift at intramiocardial endothelial cells. Circulation 1995;92:1491–98.

  13. Jafri SM, Ozawa T, Mammen E, et al. Platelet function, thrombin and fibronolitic activity in patients with heart failure. Eur. Heart J 1993;14:205–12.

  14. Rengo G, Pagano G, Squizzato A, Moja L, Femminella GD, et al. Oral Anticoagulation Therapy in Heart Failure Patients in Sinus Rhythm: A Systematic Review and Meta-Analysis. PLoS ONE 2013;8(1): e52952. doi:10. 1371/journal.

  15. Lip GY, Piotrponikowski P, et al. Throm-boembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost 2012;108(6):1009–22.

  16. Camm AJ, Kirchhof P, Lip GY, et al.Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Eur Heart J 2010;31:2369–29.

  17. Banerjee A, Taillandier S, Olesen JB, et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail 2012;14:295–301.


Похожие статьи


Бионика Медиа